RU2211215C2 - Амиды кислот, способ их получения и фармацевтическая композиция на их основе - Google Patents

Амиды кислот, способ их получения и фармацевтическая композиция на их основе Download PDF

Info

Publication number
RU2211215C2
RU2211215C2 RU2001126120/04A RU2001126120A RU2211215C2 RU 2211215 C2 RU2211215 C2 RU 2211215C2 RU 2001126120/04 A RU2001126120/04 A RU 2001126120/04A RU 2001126120 A RU2001126120 A RU 2001126120A RU 2211215 C2 RU2211215 C2 RU 2211215C2
Authority
RU
Russia
Prior art keywords
compound
salt
formula
mixture
dementia
Prior art date
Application number
RU2001126120/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2001126120A (ru
Inventor
Акира ЯМАДА (JP)
Акира Ямада
Сатоси АОКИ (JP)
Сатоси АОКИ
Original Assignee
Фудзисава Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фудзисава Фармасьютикал Ко., Лтд. filed Critical Фудзисава Фармасьютикал Ко., Лтд.
Publication of RU2001126120A publication Critical patent/RU2001126120A/ru
Application granted granted Critical
Publication of RU2211215C2 publication Critical patent/RU2211215C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
RU2001126120/04A 1999-02-26 2000-02-03 Амиды кислот, способ их получения и фармацевтическая композиция на их основе RU2211215C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8912A AUPP891299A0 (en) 1999-02-26 1999-02-26 New 6-membered cyclic compounds
AUPP8912 1999-02-26

Publications (2)

Publication Number Publication Date
RU2001126120A RU2001126120A (ru) 2003-07-20
RU2211215C2 true RU2211215C2 (ru) 2003-08-27

Family

ID=3813111

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001126120/04A RU2211215C2 (ru) 1999-02-26 2000-02-03 Амиды кислот, способ их получения и фармацевтическая композиция на их основе

Country Status (19)

Country Link
EP (1) EP1159258B1 (enExample)
JP (1) JP4089159B2 (enExample)
KR (1) KR100620406B1 (enExample)
CN (1) CN1170814C (enExample)
AR (1) AR029618A1 (enExample)
AT (1) ATE282022T1 (enExample)
AU (2) AUPP891299A0 (enExample)
BR (1) BR0010225A (enExample)
CA (1) CA2371827C (enExample)
DE (1) DE60015732T2 (enExample)
DK (1) DK1159258T3 (enExample)
ES (1) ES2226775T3 (enExample)
HK (1) HK1044934B (enExample)
HU (1) HUP0200116A3 (enExample)
PT (1) PT1159258E (enExample)
RU (1) RU2211215C2 (enExample)
TR (1) TR200102494T2 (enExample)
TW (1) TWI225856B (enExample)
WO (1) WO2000051970A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
ATE252386T1 (de) 1998-12-24 2003-11-15 Janssen Pharmaceutica Nv Galantamin-zusammensetzung mit gesteuerter freisetzung
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
AR035431A1 (es) 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
WO2003097586A1 (en) * 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
CA2535036C (en) 2003-08-06 2015-11-24 Senomyx, Inc. Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
KR101387563B1 (ko) 2006-04-21 2014-04-25 세노믹스, 인코포레이티드 고효능의 조미용 향료를 포함하는 식품 조성물 및 이의 제조 방법
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR075401A1 (es) 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
JP2025066196A (ja) * 2022-03-14 2025-04-23 国立大学法人東北大学 認知機能改善剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797419A (en) * 1986-11-03 1989-01-10 Warner-Lambert Company Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
EP0306375A1 (fr) * 1987-08-07 1989-03-08 Synthelabo Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique
EP0343961A3 (en) * 1988-05-24 1991-01-16 American Home Products Corporation Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity
WO1991001979A1 (fr) * 1989-08-02 1991-02-21 Fujisawa Pharmaceutical Co., Ltd. Nouveaux derives d'aminopiperazine
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8287M (enExample) * 1968-12-31 1970-11-09
JPH06107544A (ja) * 1992-09-29 1994-04-19 Taisho Pharmaceut Co Ltd コリン作動性神経不全の改善・治療薬
JPH06298732A (ja) * 1993-02-16 1994-10-25 Taisho Pharmaceut Co Ltd インドール誘導体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797419A (en) * 1986-11-03 1989-01-10 Warner-Lambert Company Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
EP0306375A1 (fr) * 1987-08-07 1989-03-08 Synthelabo Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique
EP0343961A3 (en) * 1988-05-24 1991-01-16 American Home Products Corporation Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity
WO1991001979A1 (fr) * 1989-08-02 1991-02-21 Fujisawa Pharmaceutical Co., Ltd. Nouveaux derives d'aminopiperazine
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность

Also Published As

Publication number Publication date
JP2002538132A (ja) 2002-11-12
AR029618A1 (es) 2003-07-10
TR200102494T2 (tr) 2002-01-21
KR100620406B1 (ko) 2006-09-13
CN1170814C (zh) 2004-10-13
HK1044934A1 (en) 2002-11-08
AUPP891299A0 (en) 1999-03-25
CA2371827A1 (en) 2000-09-08
CA2371827C (en) 2008-06-10
TWI225856B (en) 2005-01-01
DK1159258T3 (da) 2005-02-14
PT1159258E (pt) 2005-02-28
JP4089159B2 (ja) 2008-05-28
CN1341095A (zh) 2002-03-20
ATE282022T1 (de) 2004-11-15
AU2325700A (en) 2000-09-21
HK1044934B (zh) 2005-06-03
HUP0200116A2 (hu) 2002-05-29
ES2226775T3 (es) 2005-04-01
EP1159258A1 (en) 2001-12-05
HUP0200116A3 (en) 2002-11-28
DE60015732T2 (de) 2005-03-31
AU766655B2 (en) 2003-10-23
EP1159258B1 (en) 2004-11-10
KR20010102140A (ko) 2001-11-15
BR0010225A (pt) 2002-01-22
DE60015732D1 (de) 2004-12-16
WO2000051970A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
EP1140836B1 (en) Amide compounds
RU2211215C2 (ru) Амиды кислот, способ их получения и фармацевтическая композиция на их основе
JPH11508558A (ja) ピリジノン トロンビン阻害剤
JPH08176145A (ja) アロイル−ピペリジン誘導体
JPH0570463A (ja) Ｎ−アシル−２，３−ベンゾジアゼピン誘導体、その製造法、それを含有する製剤組成物、およびその製造法
JP2003514777A (ja) フィブリノゲン依存性血小板凝集の阻害剤としてのピリジル含有スピロ環化合物
JP3897594B2 (ja) ミクロソームトリグリセリド輸送タンパク質およびアポリポタンパク質分泌の阻害剤として有用なカルボキサミド
JP2000511173A (ja) 一酸化窒素産生阻害剤としての新規なインドリルおよびベンゾフラニルカルボキサミド
CA2219261A1 (en) Antithrombotic amidinotetrahydropyridylalanine derivatives
JPH07278114A (ja) ニューロテンシンに対して活性な置換１−ナフチル−３−ピラゾールカルボキサミド、その製造方法およびそれを含有する薬学的組成物
US6664293B2 (en) Amide compounds for the potentiation of cholinergic activity
US5025033A (en) Alkylene diamines
JPH11130750A (ja) 新規誘導体
JP2022524571A (ja) 炎症性疾患を処置するためのアミノ酸誘導体
EP1345899A1 (en) Compounds
MXPA01008252A (en) Amide compounds for the potentiation of cholinergic activity
JPH06184074A (ja) １−アルコキシナフタレン−２−カルボキサミド誘導体、その製法並びに該誘導体を含有する医薬組成物
JPWO1995000502A1 (ja) 新規合成中間体およびアミノピペラジン誘導体の製造法
WO2002098871A1 (en) Phenylcarboxamides and process for preparation thereof
MX2007007893A (es) Antagonistas del receptor 5-ht7.
JPH10291979A (ja) １，２，３，４−テトラヒドロイソキノリン−３−カルボン酸ターシャリーブチルアミドの製造方法
JPWO1999009001A1 (ja) フェニルエタノールアミノテトラリン誘導体および気管支拡張剤
HK1138194A (en) Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
RH4A Copy of patent granted that was duplicated for the russian federation

Effective date: 20060227

MM4A The patent is invalid due to non-payment of fees

Effective date: 20100204